Skip to main content
. 2022 Feb 8;13(2):129. doi: 10.1038/s41419-022-04565-7

Fig. 4. Exosomal miR-7-5p enhanced the anticancer effect of Everolimus in vitro.

Fig. 4

Indicated A549 cells were treated with or without Everolimus at the settled time. The cell proliferative ability was determined by A CCK8 assay and B cell clone-formation assay. The cell migration and invasive ability was determined by C cell scratch test and D transwell matrigel assay. A549 cells were treated with indicated exosomes or Everolimus for settled times. The cell proliferative ability was determined by E CCK8 assay and F cell clone-formation assay. The cell migrating and invasive ability was determined by G cell scratch test and H transwell matrigel assay. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control.